Adam’s Biotech Scorecard is a new subscriber-only newsletter focusing on biotech developments, with the inaugural edition discussing Viking Therapeutics. The company’s dual-acting GLP-1/GIP treatment for obesity, VK2735, has shown impressive weight loss results with minimal side effects, making it a strong competitor to existing obesity treatments. With a stock price increase of 800% and a market value of $9 billion, Viking Therapeutics is now a prime acquisition target for pharmaceutical companies. The newsletter is aimed at keeping subscribers informed about such potential breakthroughs in the biotech industry.
Source link
A closer look at Viking Therapeutics, PDS Biotech
